Please login to the form below

Not currently logged in
Email:
Password:

necitumumab

This page shows the latest necitumumab news and features for those working in and with pharma, biotech and healthcare.

Lilly wins on appeal in Alimta vitamin regimen dispute

Lilly wins on appeal in Alimta vitamin regimen dispute

Stemming the decline in Alimta will give Lilly more time to build sales momentum for newer products such as rheumatoid arthritis treatment Olumiant (baricitinib) and NSCLC therapy Portrazza (necitumumab).

Latest news

More from news
Approximately 3 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Pharma deals during January 2013 Pharma deals during January 2013

    In a similar vein, Bristol Myers Squibb (BMS) confirmed that it had returned the rights to necitumumab (IMC-11F8) a next generation Erbitux in phase III for non-small cell lung

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics